Levemir Flextouch (Insulin Detemir)

Insulin detemir binds to insulin receptors on muscle and fat cells, activating intracellular pathways that move glucose transporters to the cell surface. This enhances glucose uptake from the bloodstream. Its fatty‑acid side chain increases binding to albumin, slowing absorption and creating a prolonged, relatively flat insulin effect that lasts up to 24 hours.

The dose of Levemir Flextouch is individualized by the prescribing healthcare professional. It is based on factors such as the patient’s current blood glucose patterns, total daily insulin requirements, renal and hepatic function, and any concurrent medications. Patients should follow the dose adjustments recommended by their prescriber.

Insulin detemir is classified as a pregnancy‑category drug only after a risk‑benefit assessment. It may be used during pregnancy or lactation if the potential benefits to the mother outweigh any possible risks to the fetus or infant. Decisions should be made together with a qualified obstetric or endocrine specialist.

To place an order, submit an enquiry on the Levemir Flextouch product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Levemir Flextouch (insulin detemir) offers a relatively flat 24‑hour profile with a lower risk of nocturnal hypoglycemia compared with some intermediate‑acting insulins. Unlike insulin glargine, detemir’s albumin binding results in a slightly shorter duration, often requiring twice‑daily dosing in some patients, but it is generally well tolerated and has a stable formulation.

Levemir Flextouch should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the pen in its original packaging, protect it from light, and avoid freezing. Once in use, the pen may be kept at controlled room temperature (up to 30 °C) for up to 28 days, but it should not be exposed to extreme heat.

Levemir Flextouch is administered subcutaneously using the prefilled pen. Injection sites include the abdomen, thigh, or upper arm, rotating sites with each dose to reduce lipodystrophy. The pen is designed for easy dose selection and delivery; patients should be trained by a healthcare professional on proper technique and needle disposal.

The most serious risks include severe hypoglycemia, which can cause confusion, loss of consciousness, or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood glucose and to seek immediate medical attention if a severe reaction occurs.

Levemir Flextouch should not be used by individuals with a known hypersensitivity to insulin detemir or any of the pen’s excipients. It is also contraindicated in patients experiencing hypoglycemia unawareness without proper monitoring, and in those for whom basal insulin therapy is not indicated, such as certain cases of type 2 diabetes managed solely with oral agents.